These RevTMs are bispecific Abs (bsAbs) that consist of two scFvs, the first one with specificity for the RevCAR epitope E5B9 or E7B6 and the second one directed against the AML associated antigen CD33 or CD123. This evidence concerns the gene CD33 and acute myeloid leukemia.